Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01872689 · ClinicalTrials.gov registry record · Phase 2
A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 505
- Enrollment target
NCT01872689: Completed Phase 2 study, sponsored by Hoffmann-La Roche.
NCT01872689 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 505 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (280% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01872689, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 505 participants
- Enrollment target
Study Summary
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with pirfenidone background therapy in participants with IPF. Participants will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.
Primary Outcome
Annualized rates of decrease (slope throughout time from baseline to Week 52) for percent predicted FVC was assessed and reported. FVC is a standard pulmonary function test. FVC is defined as the volume of air that can forcibly be blown out after full inspiration in the upright position, measured in liters. Predicted FVC is based on sex, age, and height of a person. Percent predicted FVC (in %) = \[(observed FVC)/(predicted FVC)\]\*100.
Interventions
- DRUG Placebo
- DRUG Lebrikizumab
- DRUG Pirfenidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2013-10-13 |
| Est. Completion | 2017-11-06 |
| Phase | Phase 2 |
What the finished NCT01872689 record still lists
NCT01872689 is an interventional study that assigns participants to a tested intervention. The registered 505 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (280% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01872689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01872689 about?
NCT01872689 is a clinical study titled "A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)". This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with pirfenidone background therapy in participants with IPF. Participants wil...
What is the current status of trial NCT01872689?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 505 participants. The study started on 2013-10-13. Estimated completion is 2017-11-06.
What interventions are being tested in trial NCT01872689?
The interventions under investigation include: Placebo (DRUG), Lebrikizumab (DRUG), Pirfenidone (DRUG).
Who is sponsoring clinical trial NCT01872689?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01872689's enrollment target sits among peer trials
505 69th of 2000 higher than 1,932 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05069428 · 506 participants · Phase 4
Delirium Reduction With Ramelteon
- NCT05797168 · 506 participants · Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- NCT05846282 · 504 participants · NA
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
- NCT06072131 · 504 participants · Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI